Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOadjuvant chemotherapy only compared with standard treatment for locally advanced rectal cancer
2024-517748-76-00Phase 2Authorised
- Sponsor
- Region Zealand
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine, oxaliplatin, fluorouracil and folinic acid in rectal cancer (2 arms), sponsored by Region Zealand. Primary endpoint: Disease free survival. Planned start Oct 2024; status: authorised.
02
Drugs
capecitabineoxaliplatinfluorouracilfolinic acid
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-517748-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517748-76-00.